Category

• Pipeline2

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Clinical Trials2
• AMD1
• Injections1
• Retina1
• Thyroid Eye Disease (ted)1
• Wet Amd1

• Organizations: Innovent Biologics✕

Clear all

Pipeline

Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint

Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.

Pipeline

First patient dosed in phase 2, China-based TED trial

The RESTORE trial is assessing the proptosis responder rate following dosage of IBI311, an IGF-1R monoclonal antibody.